神経医科学研究所は、
神経系を固定的な構造体としてではなく、
環境刺激および生体内部の調節機構に応答して
動的に再編成される適応的システムとして捉える
ANeT理論（Adaptive Neuroplasticity Theory／神経適応可塑性理論）を中核概念に、
非侵襲的な神経治療技術の研究開発と
臨床応用を通じて、多様な疾患の根本的理解と
機能回復の可能性を探究してまいりました。

私はこれまで、
レーザー医療の開発を専門とし、
自然治癒が困難とされてきた
神経および皮膚の再生領域において、
基礎研究と臨床実践の両面から取り組んでまいりました。

こうした経験を基盤に、
神経の可塑性と適応機構を臨床的に活用する
治療体系として、ANeT理論に基づく
神経治療法「シナプス療法」の研究と実践を進めています。
特に、顔面神経麻痺、対麻痺、四肢麻痺などの
機能障害に対し、薬剤・手術・機器に依存せず、
徒手による介入を通じて神経回路の
機能的再構築を促すアプローチを追究してまいりました。

2021年の研究所設立以来、
国内外における臨床症例は7万件を超え、
2025年には世界初となる
シナプス療法専門施設「シナプスセンター」を
チュニジアに開設いたしました。

複数の学会において有効性が報告され、
パーキンソン病、斜視、神経麻痺、ALSなどに対する
改善効果についても、科学的エビデンスの蓄積が進められています。

当研究所の最大の強みは、
博士、医師、薬剤師、理学療法士、看護師、柔道整復師など、
多分野の専門家が学術的背景の垣根を越えて
協働する研究環境にあります。

臨床現場で得られる知見を迅速に共有し、
机上の理論にとどまることなく、
ANeT理論の検証と発展を
日々の実践の中で積み重ねています。

私たちは、薬物療法、運動療法、心理療法、放射線療法といった
従来の枠組みに留まらない、
新たな選択肢としての神経治療の可能性を、
国際社会に向けて提案しています。

また、その取り組みは日本国内にとどまらず、
医療資源が限られた地域や発展途上国への
技術移転にも力を注いでいます。

これまでに、アジア、アラブ諸国、
ヨーロッパ、アメリカをはじめとする各地域において
講演および技術提供を行い、
多くの国際的な医療機関および大学との
連携を築いてまいりました。

今後も、病院、大学、クリニック、
地域医療機関との協働を一層深め、
神経疾患、慢性疾患、精神疾患、急性期障害に対する
革新的な治療法の確立と、予防的アプローチの開発に
尽力してまいります。

基礎研究と臨床現場を結ぶ架け橋となることを使命とし、
ANeT理論の深化とその社会的実装を通じて、
世界中の「痛み」や「苦しみ」に向き合う人々の
希望となる医療の実現を追求してまいります。
今後とも、神経医科学研究所の活動に
ご理解とご支援を賜りますよう、
心よりお願い申し上げます。

The Institute for Neuroscience conceptualizes the nervous system not as a fixed structural entity, but as an adaptive system that is dynamically reorganized in response to environmental stimuli and intrinsic regulatory mechanisms.

At the core of our research and clinical activities lies the ANeT Theory (Adaptive Neuroplasticity Theory / Neural Adaptive Plasticity Theory), which serves as a foundational framework for the development and clinical application of non-invasive neurotherapeutic technologies, aimed at advancing the fundamental understanding of diverse neurological conditions and exploring pathways toward functional recovery.

Throughout my career, I have specialized in the development of laser-based medical technologies and have engaged in both basic research and clinical practice within the fields of neural and cutaneous regeneration, particularly in areas where spontaneous recovery has traditionally been considered limited.

Building upon this experience, we have advanced the research and implementation of a neurotherapeutic approach, Synapse Therapy, which is grounded in the principles of the ANeT Theory and seeks to clinically harness the mechanisms of neuroplasticity and neural adaptation.

In particular, we have pursued an approach that promotes the functional reorganization of neural circuits through manual, non-pharmacological intervention, without reliance on medications, surgical procedures, or medical devices, in the treatment of functional impairments such as facial nerve palsy, paraplegia, and limb paralysis.

Since the establishment of the Institute in 2021, the number of clinical cases conducted both domestically and internationally has exceeded 70,000. In 2025, we inaugurated the world’s first specialized center dedicated to neurotherapeutic practice based on Synapse Therapy, the Synapse Center, in Tunisia.

The effectiveness of our approach has been reported across multiple academic conferences, and scientific evidence continues to be accumulated regarding its potential benefits in conditions including Parkinson’s disease, strabismus, neurological paralysis, and amyotrophic lateral sclerosis (ALS).

One of the Institute’s greatest strengths lies in its interdisciplinary research environment, where scholars and practitioners from diverse professional backgrounds—PhDs, physicians, pharmacists, physical therapists, nurses, and licensed manual therapy specialists—collaborate beyond conventional disciplinary boundaries.

Clinical insights obtained in practice are rapidly shared and systematically examined, ensuring that the ANeT Theory is not confined to theoretical discourse, but is continuously validated and refined through ongoing empirical application.

We seek to propose, to the international community, new possibilities in neurotherapeutic intervention that extend beyond the conventional paradigms of pharmacological, physical, psychological, and radiological therapies.

Our initiatives are not limited to Japan alone. We are also committed to the transfer of knowledge and clinical techniques to regions with limited medical resources and to developing and emerging countries.

To date, we have delivered lectures and provided technical expertise across Asia, the Arab world, Europe, and the Americas, and have established collaborative partnerships with numerous international medical institutions and universities.

Moving forward, we will continue to deepen our collaboration with hospitals, universities, clinics, and community-based healthcare institutions, striving to establish innovative therapeutic and preventive strategies for neurological disorders, chronic diseases, psychiatric conditions, and acute-phase impairments.

With a commitment to serving as a bridge between fundamental research and clinical practice, we will pursue the advancement and societal implementation of the ANeT Theory, and remain dedicated to realizing a form of medicine that offers hope to individuals worldwide who confront pain and suffering.

Since 2004, he has been engaged in the research and development of blue-violet laser technologies, which form the foundation of next-generation optical systems, including Blu-ray–based platforms. He conducted foundational research into nanoscale optical applications and their potential deployment in medical imaging diagnostics and non-invasive therapeutic technologies.

In 2005, he initiated the conceptualization and development of a radiation-free transmission diagnostic system, aiming to establish a safer medical imaging modality as an alternative to conventional X-ray–based diagnostic technologies.

In 2008, he was selected as a Research Fellow under the Ministry of Education, Culture, Sports, Science and Technology (MEXT) Global COE Program, and in July of the same year, he was appointed International Project Manager. In this role, he led interdisciplinary research teams and facilitated international collaborative initiatives bridging regenerative medicine and medical device development.

In 2009, he received the Best Award at an international symposium jointly hosted by the Massachusetts Institute of Technology (MIT) and Stanford University, where his work was internationally recognized for its high level of implementation capability and applicability in next-generation medical technologies.

Beginning in 2010, he conducted research on immortalized cell lines and long-term cell culture techniques, contributing to the establishment of stable cell supply systems within the field of regenerative medicine.

In 2014, he successfully established and scaled the production of growth factor–based skin regeneration technologies. These innovations, aimed at applications in wound healing and aesthetic medicine, led to the successful commercialization of related products.

In 2016, he advanced research and development initiatives involving both human stem cells and plant-derived stem cells, contributing to the foundational framework of next-generation regenerative medicine through the medical application of cell-derived components and the reevaluation of natural biological resources.

In 2018, he developed a conversational training program for healthy individuals designed to facilitate more effective communication with patients living with dementia. This initiative gained recognition as a pioneering approach in non-pharmacological cognitive care interventions.

In 2020, in response to the global spread of COVID-19, he established a deep ultraviolet (DUV) laser–based viral inactivation technology, demonstrating high efficacy as a non-contact infection prevention measure. Concurrently, he initiated research and development into novel non-pharmacological preventive technologies aimed at infection control.

In 2021, he proposed a novel neurotherapeutic approach, Synapse Therapy, as a response to neurological disorders that have proven difficult to address through conventional medical interventions. This approach does not rely on pharmaceuticals, medical devices, or surgical procedures, and is grounded in a clinical model based on neural plasticity and adaptive mechanisms, promoting non-invasive and immediate functional improvement as a new paradigm in rehabilitation.

In 2022, he established the Neural Medical Institute of Technology as an educational organization dedicated to the systematic training of healthcare professionals and practitioners in neurotherapeutic techniques. The number of participants exceeded 1,000, and clinical applications rapidly expanded nationwide.

In the same year, he introduced a novel non-surgical treatment for acute strabismus, thereby extending the clinical potential of non-invasive approaches to neural function.

In 2023, he developed passive rehabilitation methods addressing post-COVID-19 sequelae, including impairments in taste and olfaction, as well as periarticular inflammation. He further established intervention programs aimed at improving autonomic nervous system function, thereby providing a comprehensive approach to neural regulation and functional recovery.

In 2024, he advanced the research and development of a visual neural stimulation tool, the “Kaleidoscope,” designed to enhance cognitive activation and attentional function in older adults.

In the same year, he was appointed as a final judge for the National Manual Therapy Championship of Japan, where he introduced neuroscientific perspectives into the evaluation of therapeutic techniques.

In 2025, he inaugurated the world’s first specialized neurotherapeutic facility, the Synapse Center, in Tunisia and assumed the role of Director. Through this initiative, he accelerated the transfer of medical technologies and the establishment of international cooperation frameworks across Africa and the Middle East.

In the same year, his presentation at the Japanese Society of Fatigue Science on immediate functional improvements in patients with Parkinson’s disease through a peripheral nervous system–based approach generated significant attention as a breakthrough in non-pharmacological therapy.

He was also appointed Executive Committee Chair of the Well-being Conference in the Principality of Monaco and assumed the role of Board Member of the WFCMS Rheumatology Specialist Committee.